Transform your practice, clinically and financially.
Succeed under value-based care payment models by making care decisions with patient and business insights
Find value in a
Improve performance and patient experience with our value-based, precision oncology solutions
Make member savings part of your payment model.
Manage value-based provider networks and at-risk patients, while driving savings with cost and quality improvements
Integra Connect solutions can accelerate adoption of value-based, precision medicine efforts across the care continuum:
Solutions for Providers
Deliver high quality patient care and experiences, while managing costs.
Advance research, improve drug development and maximize revenue.
Revenue Cycle Management
Boost collections, accelerate the billing process, and find hidden growth potential.
Identify at-risk patients and populations for proactive intervention, optimize costs and quality performance, and excel under value-based payment models.
Understand the patient journey, improve work efficiency, integrate care and information flows, and easily analyze and report performance.
Precision Medicine Solutions
for Life Sciences
Identify opportunities for clinical research and drug development, support pipeline, and launch medicines for the benefit of patients
How Integra Connectis different
Integra Connect is driven to make specialty care practices clinically and financially successful through value-based, precision medicine. While other companies may focus on one of these areas, Integra Connect’s combined approach means providers, payers, and life sciences companies can harness value-based, precision medicine principles to improve their decision-making and make a difference in patients’ lives.SCHEDULE A DEMO
Make data-driven decisions with our Precision Medicine platform
Integra Connect’s precision medicine platform is the industry’s most comprehensive and advanced solution for providing personalized patient care.LEARN MORE
Precision Medicine Solutions for Oncology Practices
Adopt a targeted, personalized and patient-centered approach to care with the aid of advanced analytics and expert guidance.
Precision Medicine Solutions for Life Sciences Companies
Identify opportunities for drug development, HEOR research, and improved patient outcomes with our industry-leading data services.
Our leadership team is composed of experts with extensive real-world experience working in clinical settings.
Charles Saunders MD
Chief Executive Officer
Charles Saunders is Chief Executive Officer at Integra Connect. Dr. Saunders is a physician executive who combines a clinical, business and technology background.Read More
Jeffrey A. Scott MD
Chief Medical Officer
Dr. Scott is the Chief Medical Officer. He has significant experience building market leading initiatives in Community Practice and GPOs, bringing a multitude of innovative programs and organizations to the marketplace.Read More
Chief Financial Officer
Gira Shah is Chief Financial Officer at Integra Connect. As CFO, Ms. Shah is responsible for overall financial management of the company and for multiple corporate functions including controllership, treasury, tax, and long-term strategic planning.Read More
President, Global Operations
Jitendra Gupta is President, Global Operations at Integra Connect, where he is responsible for managing delivery of services to Integra Connect’s clients. Jitendra is a seasoned healthcare professional with over fifteen years of consulting and operations experience.Read More
Best practices for optimising performance under value-based reimbursement models, developed by our in-house experts.
Access content and gain insights about the role data plays in healthcare transformation and how data can empower informed decisions.
See the latest announcements, news and media coverage.
Watch videos and interviews about the future of healthcare in a value-based ecosystem including quality improvement and much more.
What the Industry is SayingAbout Integra Connect
Integra Connect Statement on the Enhancing Oncology Model
Integra Connect, LLC. is pleased that the Centers for Medicare & Medicaid Services’ (CMS) Center for Medicare & Medicaid Innovation (CMMI) announced the next iteration of its value-based, oncology care…Read more
Integra Connect to Share Study Results Underscoring the Importance of Early and Rapid Genetic Testing for Improved Survival Rates in Patients with Newly Diagnosed, Stage 4 Non-Small Cell Lung Cancer
WEST PALM BEACH, Fla. Integra Connect, the leading provider of value-based, precision medicine solutions and services for specialty care, will present findings from a retrospective observational study in newly diagnosed, stage 4 non-small cell lung cancer (NSCLC) that demonstrates improved patient survival rates when molecular testing is applied prior to initiating treatment. The results will be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting on June 4 at 1:15 p.m. CST.Read more
New real-world data show potential of Trilaciclib to reduce the substantial burden of myelosuppression in patients with extensive-stage small-cell lung cancer treated with chemotherapy
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced results of a retrospective, observational study describing the substantial burden of myelosuppression and its impact on healthcare resource utilization (HCRU) in 3,277 patients being treated with chemotherapy for extensive-stage small-cell lung cancer (ES-SCLC). The study also described patient outcomes from 21 patients receiving trilaciclib prior to chemotherapy; of these, 17 received commercial trilaciclib in the real-world setting, and four received trilaciclib in clinical trials.Read more